<!DOCTYPE html><html lang="en" class="dark"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/e4af272ccee01ff0-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="stylesheet" href="/_next/static/css/8d323862949ffad9.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js"/><script src="/_next/static/chunks/ceb5afef-fd730bca4742d10d.js" async=""></script><script src="/_next/static/chunks/156-5c70558397be49ef.js" async=""></script><script src="/_next/static/chunks/main-app-f896963268641fe0.js" async=""></script><script src="/_next/static/chunks/863-822c2cde35e02348.js" async=""></script><script src="/_next/static/chunks/app/layout-fb78cfc571d4c3d6.js" async=""></script><title>Unloxcyt Market Survey - Interactive Presentation</title><meta name="description" content="Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__className_f367f3 h-1080px w-1920px"><!--$!--><template data-dgst="BAILOUT_TO_CLIENT_SIDE_RENDERING"></template><!--/$--><div class="relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white"><div class="flex flex-col w-full h-full"><div class="flex-none bg-slate-800/90 p-6 flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="48" height="48" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-file-text text-blue-400"><path d="M15 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7Z"></path><path d="M14 2v4a2 2 0 0 0 2 2h4"></path><path d="M10 9H8"></path><path d="M16 13H8"></path><path d="M16 17H8"></path></svg><h1 class="text-6xl font-bold text-white">Executive Summary</h1></div><div class="flex-1 min-h-0 grid grid-cols-[1fr_1fr] grid-rows-[auto_1fr] gap-8 p-8"><div class="col-span-2 bg-slate-800 p-6 border-l-4 border-blue-400 rounded-lg"><p class="text-3xl leading-relaxed">Unloxcyt (cosibelimab-ipdl) is the first and only FDA-approved PD-L1 inhibitor for metastatic or locally advanced cutaneous squamous cell carcinoma, entering a U.S. market exceeding $1 billion annually with peak sales potential of $1.0-1.6 billion.</p></div><div class="flex flex-col gap-6"><div class="bg-slate-800/80 p-4 rounded-lg flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-green-400"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><div><p class="text-xl text-gray-300">FDA Approval Date</p><p class="text-4xl font-bold text-white">December 13, 2024</p></div></div><div class="bg-slate-800/80 p-4 rounded-lg flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-dollar-sign text-blue-400"><line x1="12" x2="12" y1="2" y2="22"></line><path d="M17 5H9.5a3.5 3.5 0 0 0 0 7h5a3.5 3.5 0 0 1 0 7H6"></path></svg><div><p class="text-xl text-gray-300">Acquisition Value</p><p class="text-4xl font-bold text-white">$416M</p></div></div><div class="bg-slate-800/80 p-4 rounded-lg flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-green-400"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><div><p class="text-xl text-gray-300">U.S. Market Size</p><p class="text-4xl font-bold text-white">$1B+</p></div></div><div class="bg-slate-800/80 p-4 rounded-lg flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-target text-purple-400"><circle cx="12" cy="12" r="10"></circle><circle cx="12" cy="12" r="6"></circle><circle cx="12" cy="12" r="2"></circle></svg><div><p class="text-xl text-gray-300">Peak Sales Potential</p><p class="text-4xl font-bold text-white">$1.0-1.6B</p></div></div><div class="bg-slate-800/80 p-4 rounded-lg flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-activity text-green-400"><path d="M22 12h-2.48a2 2 0 0 0-1.93 1.46l-2.35 8.36a.25.25 0 0 1-.48 0L9.24 2.18a.25.25 0 0 0-.48 0l-2.35 8.36A2 2 0 0 1 4.49 12H2"></path></svg><div><p class="text-xl text-gray-300">Objective Response Rate</p><p class="text-4xl font-bold text-white">47-48%</p></div></div></div><div class="bg-slate-800/80 p-6 rounded-lg"><h3 class="text-4xl font-bold text-purple-400 mb-6">Key Strategic Highlights</h3><div class="space-y-4"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">First-in-class PD-L1 mechanism with ADCC activity providing differentiation from PD-1 inhibitors</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Strong clinical efficacy with durable responses in Phase 1 trial (47% ORR, not reached median duration)</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Sun Pharma acquisition provides global commercialization infrastructure and dermatology expertise</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Competitive landscape dominated by Keytruda and Libtayo presents both challenges and opportunities</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">European expansion planned with EMA/UK MHRA submissions adding $250-400M peak sales potential</p></div></div></div></div><div class="flex-none p-4 text-right"><p class="text-xl text-gray-400">2</p></div></div></div><script src="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/e4af272ccee01ff0-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/css/8d323862949ffad9.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"3:I[5616,[],\"\"]\n5:I[6146,[],\"\"]\n6:I[4411,[],\"\"]\n7:\"$Sreact.suspense\"\n8:I[7256,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"KeyboardNavigation\"]\n9:I[5407,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"SlideNavigation\"]\nb:I[7141,[],\"\"]\nc:[]\n"])</script><script>self.__next_f.push([1,"0:[\"$\",\"$L3\",null,{\"buildId\":\"DkpgZd6XOJjDaY981EGFp\",\"assetPrefix\":\"\",\"urlParts\":[\"\",\"pages\",\"2\"],\"initialTree\":[\"\",{\"children\":[\"pages\",{\"children\":[\"2\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"pages\",{\"children\":[\"2\",{\"children\":[\"__PAGE__\",{},[[\"$L4\",[\"$\",\"div\",null,{\"className\":\"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex flex-col w-full h-full\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-none bg-slate-800/90 p-6 flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":48,\"height\":48,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-file-text text-blue-400\",\"children\":[[\"$\",\"path\",\"1rqfz7\",{\"d\":\"M15 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7Z\"}],[\"$\",\"path\",\"tnqrlb\",{\"d\":\"M14 2v4a2 2 0 0 0 2 2h4\"}],[\"$\",\"path\",\"b1mrlr\",{\"d\":\"M10 9H8\"}],[\"$\",\"path\",\"t4e002\",{\"d\":\"M16 13H8\"}],[\"$\",\"path\",\"z1uh3a\",{\"d\":\"M16 17H8\"}],\"$undefined\"]}],[\"$\",\"h1\",null,{\"className\":\"text-6xl font-bold text-white\",\"children\":\"Executive Summary\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex-1 min-h-0 grid grid-cols-[1fr_1fr] grid-rows-[auto_1fr] gap-8 p-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"col-span-2 bg-slate-800 p-6 border-l-4 border-blue-400 rounded-lg\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-3xl leading-relaxed\",\"children\":\"Unloxcyt (cosibelimab-ipdl) is the first and only FDA-approved PD-L1 inhibitor for metastatic or locally advanced cutaneous squamous cell carcinoma, entering a U.S. market exceeding $1 billion annually with peak sales potential of $1.0-1.6 billion.\"}]}],[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-4 rounded-lg flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-green-400\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"FDA Approval Date\"}],[\"$\",\"p\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"December 13, 2024\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-4 rounded-lg flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-dollar-sign text-blue-400\",\"children\":[[\"$\",\"line\",\"7eqyqh\",{\"x1\":\"12\",\"x2\":\"12\",\"y1\":\"2\",\"y2\":\"22\"}],[\"$\",\"path\",\"1b0p4s\",{\"d\":\"M17 5H9.5a3.5 3.5 0 0 0 0 7h5a3.5 3.5 0 0 1 0 7H6\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Acquisition Value\"}],[\"$\",\"p\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"$$416M\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-4 rounded-lg flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-green-400\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"U.S. Market Size\"}],[\"$\",\"p\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"$$1B+\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-4 rounded-lg flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-target text-purple-400\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"circle\",\"1vlfrh\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"6\"}],[\"$\",\"circle\",\"1c9p78\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"2\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Peak Sales Potential\"}],[\"$\",\"p\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"$$1.0-1.6B\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-4 rounded-lg flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":36,\"height\":36,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-activity text-green-400\",\"children\":[[\"$\",\"path\",\"169zse\",{\"d\":\"M22 12h-2.48a2 2 0 0 0-1.93 1.46l-2.35 8.36a.25.25 0 0 1-.48 0L9.24 2.18a.25.25 0 0 0-.48 0l-2.35 8.36A2 2 0 0 1 4.49 12H2\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Objective Response Rate\"}],[\"$\",\"p\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"47-48%\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/80 p-6 rounded-lg\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-purple-400 mb-6\",\"children\":\"Key Strategic Highlights\"}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"First-in-class PD-L1 mechanism with ADCC activity providing differentiation from PD-1 inhibitors\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Strong clinical efficacy with durable responses in Phase 1 trial (47% ORR, not reached median duration)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Sun Pharma acquisition provides global commercialization infrastructure and dermatology expertise\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Competitive landscape dominated by Keytruda and Libtayo presents both challenges and opportunities\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"European expansion planned with EMA/UK MHRA submissions adding $250-400M peak sales potential\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex-none p-4 text-right\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-400\",\"children\":\"2\"}]}]]}]}],null],null],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\",\"2\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/8d323862949ffad9.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"dark\",\"children\":[\"$\",\"body\",null,{\"className\":\"__className_f367f3 h-1080px w-1920px\",\"children\":[[\"$\",\"$7\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L8\",null,{}],[\"$\",\"$L9\",null,{}]]}],[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":\"404\"}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],\"notFoundStyles\":[]}]]}]}]],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$La\"],\"globalErrorComponent\":\"$b\",\"missingSlots\":\"$Wc\"}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"Unloxcyt Market Survey - Interactive Presentation\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC\"}],[\"$\",\"meta\",\"4\",{\"name\":\"next-size-adjust\"}]]\n4:null\n"])</script></body></html>